Acorda named one of the 100 best workplaces for women by fortune
and great place to work
Ardsley, n.y.--(business wire)--acorda therapeutics, inc. (nasdaq:acor) has been named as one of the 100 best workplaces for women based on an independent survey by fortune and great place to work®. the survey included more than 135,600 female employees at companies of all sizes based in the united states. this recognition is based on women’s assessments of the quality and fairness of their workplace. “acorda is focused on developing medicines that can change people’s lives. to do so successfully requires close collaboration among people with a wide diversity of perspectives and experiences, and rewards based solely on performance. our culture emphasizes these values, while also fostering work/home life balance,” said denise duca, executive vice president, human resources of acorda. “we are proud that the talented women who work at acorda view this as a great place to build a career and to make valuable contributions to advancing healthcare.” in addition to being named as one of the best workplaces for women in 2015, acorda has been recognized as one of the best places to work in new york for the past five years in a row by the best companies group, ranking 3rd in 2015 among large employers (250+ associates). factors such as the fairness of promotions, access to information and leadership, level of support for employees’ personal lives, and degree of inclusiveness and connection with colleagues were inclusion criteria for the best workplaces for women list. scores also take into account how well-represented women are within the workforce, management and executive positions; how positively women experience their workplace’s fairness; and how favorable women’s experiences are compared to the 138,000 men also surveyed. the analysis showed that the companies recognized as best workplaces for women create a more consistent and inclusive environment across a range of day-to-day trust-building behaviors, including employees’ access to special recognition, fair treatment regardless of role, and management approachability. about acorda therapeutics founded in 1995, acorda therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders. acorda markets three fda-approved therapies, including ampyra® (dalfampridine) extended release tablets, 10 mg. the company has one of the leading pipelines in the industry of novel neurological therapies. acorda is currently developing a number of clinical and preclinical stage therapies. this pipeline addresses a range of disorders including post-stroke walking deficits, parkinson’s disease, epilepsy, heart failure, ms and spinal cord injury. for more information, please visit the company’s website at: www.acorda.com. forward looking statements this press release includes forward-looking statements within the meaning of the private securities litigation reform act of 1995. all statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. these statements are subject to risks and uncertainties that could cause actual results to differ materially, including the ability to realize the benefits anticipated from the civitas transaction and to successfully integrate civitas' operations into our operations; our ability to successfully market and sell ampyra in the u.s.; third party payers (including governmental agencies) may not reimburse for the use of ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of ampyra or from our other research and development programs, including cvt-301, plumiaz (diazepam) nasal spray, or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market cvt-301, plumiaz, or any other products under development; we may need to raise additional funds to finance our expanded operations and may not be able to do so on acceptable terms; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of or to successfully market fampyra outside of the u.s. and our dependence on our collaboration partner biogen in connection therewith; competition; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; and, failure to comply with regulatory requirements could result in adverse action by regulatory agencies. these and other risks are described in greater detail in acorda therapeutics' filings with the securities and exchange commission. acorda may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. forward-looking statements made in this release are made only as of the date hereof, and acorda disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this release.
